{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T13:52:49Z","timestamp":1778939569779,"version":"3.51.4"},"reference-count":95,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.schres.2026.03.003","type":"journal-article","created":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T12:34:14Z","timestamp":1773405254000},"page":"69-78","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Psychedelics for treatment of negative symptoms and depressive symptoms in schizophrenia spectrum disorder: A narrative review"],"prefix":"10.1016","volume":"292","author":[{"given":"Michel","family":"Sab\u00e9","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Grof","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathan B.","family":"Sackett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Tai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pamela","family":"Kryskow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anya","family":"Bershad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas","family":"Turkington","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo","family":"Buonarroti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"De Pieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pantelis","family":"Baniotopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mickael","family":"Eskinazi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kerem","family":"B\u00f6ge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Leucht","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federico","family":"Seragnoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L\u00e9onice","family":"Furtado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatiana Aboulafia","family":"Brakha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Logos","family":"Curtis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Kirschner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Kaiser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louise","family":"Penzenstadler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniele","family":"Zullino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikkel","family":"H\u00f8jlund","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jade","family":"Gallo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Solmi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacopo","family":"Sapienza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Bosia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"La Torre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.schres.2026.03.003_bb0005","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1001\/jamapsychiatry.2023.4685","article-title":"Single-dose synthetic psilocybin with psychotherapy for treatment-resistant bipolar type II major depressive episodes: a nonrandomized open-label trial","volume":"81","author":"Aaronson","year":"2024","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.schres.2026.03.003_bb0010","doi-asserted-by":"crossref","DOI":"10.1021\/acschemneuro.5c00667","article-title":"Zalsupindole is a nondissociative, nonhallucinogenic neuroplastogen with therapeutic effects comparable to ketamine and psychedelics","volume":"16","author":"Agrawal","year":"2025","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.schres.2026.03.003_bb0015","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.jpsychires.2022.04.037","article-title":"Real-world effectiveness of ketamine in treatment-resistant depression: a systematic review & meta-analysis","volume":"151","author":"Alnefeesi","year":"2022","journal-title":"J. Psychiatr. Res."},{"issue":"452","key":"10.1016\/j.schres.2026.03.003_bb0020","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1192\/bjp.108.452.95","article-title":"Effects of LSD-25 on relatives of schizophrenic patients","volume":"108","author":"Anastasopoulos","year":"1962","journal-title":"J. Ment. Sci."},{"issue":"3","key":"10.1016\/j.schres.2026.03.003_bb0025","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1176\/appi.ajp.162.3.441","article-title":"Remission in schizophrenia: proposed criteria and rationale for consensus","volume":"162","author":"Andreasen","year":"2005","journal-title":"Am. J. Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2026.03.003_bb0030","article-title":"Modificazioni neuro-psico-biochimiche indotte dalla dietilamide dell\u2019acido lisergico in schizofrenici e frenastenici","volume":"7","author":"Belsanti","year":"1952","journal-title":"Acta Neurol."},{"issue":"12","key":"10.1016\/j.schres.2026.03.003_bb0035","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1093\/ijnp\/pyx056","article-title":"Dopamine system dysregulation in major depressive disorders","volume":"20","author":"Belujon","year":"2017","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.schres.2026.03.003_bb0040","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2016.00045","article-title":"A review of impaired neuroplasticity in schizophrenia investigated with non-invasive brain stimulation","volume":"7","author":"Bhandari","year":"2016","journal-title":"Front. Psychiatry"},{"issue":"8","key":"10.1016\/j.schres.2026.03.003_bb0045","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/s41386-025-02097-0","article-title":"Psilocybin therapy for mood dysfunction in Parkinson\u2019s disease: an open-label pilot trial","volume":"50","author":"Bradley","year":"2025","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.schres.2026.03.003_bb0050","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41386-022-01389-z","article-title":"Towards an understanding of psychedelic-induced neuroplasticity","volume":"48","author":"Calder","year":"2023","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"10.1016\/j.schres.2026.03.003_bb0055","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1124\/pr.118.017160","article-title":"REBUS and the anarchic brain: toward a unified model of the brain action of psychedelicss","volume":"71","author":"Carhart-Harris","year":"2019","journal-title":"Pharmacol. Rev."},{"issue":"6","key":"10.1016\/j.schres.2026.03.003_bb0060","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1073\/pnas.1119598109","article-title":"Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin","volume":"109","author":"Carhart-Harris","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.schres.2026.03.003_bb0065","doi-asserted-by":"crossref","DOI":"10.3389\/fnhum.2014.00020","article-title":"The entropic brain: a theory of conscious states informed by neuroimaging research with psychedelic drugs","volume":"8","author":"Carhart-Harris","year":"2014","journal-title":"Front. Hum. Neurosci."},{"issue":"1","key":"10.1016\/j.schres.2026.03.003_bb0070","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-13282-7","article-title":"Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms","volume":"7","author":"Carhart-Harris","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.schres.2026.03.003_bb0075","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2024.1485337","article-title":"Why N,N-dimethyltryptamine matters: unique features and therapeutic potential beyond classical psychedelics","volume":"15","author":"Chaves","year":"2024","journal-title":"Front. Psychiatry"},{"issue":"Pt 12","key":"10.1016\/j.schres.2026.03.003_bb0080","doi-asserted-by":"crossref","first-page":"3296","DOI":"10.1093\/brain\/aww255","article-title":"Medial reward and lateral non-reward orbitofrontal cortex circuits change in opposite directions in depression","volume":"139","author":"Cheng","year":"2016","journal-title":"Brain"},{"key":"10.1016\/j.schres.2026.03.003_bb0085","doi-asserted-by":"crossref","first-page":"632","DOI":"10.3389\/fnins.2020.00632","article-title":"Negative symptoms of schizophrenia and dopaminergic transmission: translational models and perspectives opened by iPSC techniques","volume":"14","author":"Collo","year":"2020","journal-title":"Front. Neurosci."},{"issue":"1","key":"10.1016\/j.schres.2026.03.003_bb0090","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1600-0447.1949.tb04588.x","article-title":"KLINISCHE ERFAHRUNGEN AN GEISTESKRANKEN MIT LYSERGS\u00c4URE - DI\u00c4THYLAMID","volume":"24","author":"Condrau","year":"1949","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.schres.2026.03.003_bb0095","doi-asserted-by":"crossref","first-page":"519","DOI":"10.2147\/NDT.S225643","article-title":"Negative symptoms in schizophrenia: a review and clinical guide for recognition, assessment, and treatment","volume":"16","author":"Correll","year":"2020","journal-title":"Neuropsychiatr. Dis. Treat."},{"issue":"2","key":"10.1016\/j.schres.2026.03.003_bb1030","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1093\/schbul\/sbv146","article-title":"Altered hub functioning and compensatory activations in the connectome: a meta-analysis of functional neuroimaging studies in schizophrenia","volume":"42","author":"Crossley","year":"2016","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2026.03.003_bb0100","article-title":"Single-dose DMT reverses anhedonia and cognitive deficits via restoration of neurogenesis in a stress-induced depression model","author":"da Cruz","year":"2025","journal-title":"bioRxiv"},{"issue":"11","key":"10.1016\/j.schres.2026.03.003_bb0105","doi-asserted-by":"crossref","DOI":"10.3390\/ijms17111953","article-title":"D-lysergic acid diethylamide (LSD) as a model of psychosis: mechanism of action and pharmacology","volume":"17","author":"De Gregorio","year":"2016","journal-title":"Int. J. Mol. Sci."},{"issue":"Pt A","key":"10.1016\/j.schres.2026.03.003_bb0110","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.phrs.2016.08.022","article-title":"The hallucinogen d-lysergic diethylamide (LSD) decreases dopamine firing activity through 5-HT(1A), D(2) and TAAR(1) receptors","volume":"113","author":"De Gregorio","year":"2016","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.schres.2026.03.003_bb0115","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2021.724606","article-title":"Psychedelics and neuroplasticity: a systematic review unraveling the biological underpinnings of psychedelics","author":"de Vos","year":"2021","journal-title":"Front. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2026.03.003_bb0120","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1093\/schbul\/sbx034","article-title":"Dysfunction of large-scale brain networks in schizophrenia: a meta-analysis of resting-state functional connectivity","volume":"44","author":"Dong","year":"2018","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2026.03.003_bb0125","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.schres.2020.09.013","article-title":"Glutamate in schizophrenia: neurodevelopmental perspectives and drug development","volume":"223","author":"Egerton","year":"2020","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2026.03.003_bb0130","first-page":"1","article-title":"EPA guidance on treatment of negative symptoms in schizophrenia","volume":"64","author":"Galderisi","year":"2021","journal-title":"Eur. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2026.03.003_bb0135","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1192\/j.eurpsy.2021.11","article-title":"EPA guidance on assessment of negative symptoms in schizophrenia","volume":"64","author":"Galderisi","year":"2021","journal-title":"Eur. Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2026.03.003_bb0140","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/acps.12854","article-title":"Efficacy and safety of antidepressant augmentation of continued antipsychotic treatment in patients with schizophrenia","volume":"137","author":"Galling","year":"2018","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.schres.2026.03.003_bb1005","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/s41537-024-00478-w","article-title":"A systematic review of structural and functional magnetic resonance imaging studies on the neurobiology of depressive symptoms in schizophrenia spectrum disorders","volume":"10","author":"Gallucci","year":"2024","journal-title":"Schizophrenia"},{"issue":"3","key":"10.1016\/j.schres.2026.03.003_bb0145","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1093\/ijnp\/pyac074","article-title":"Default mode network modulation by psychedelics: a systematic review","volume":"26","author":"Gattuso","year":"2023","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"12","key":"10.1016\/j.schres.2026.03.003_bb0150","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1177\/0269881116675513","article-title":"Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial","volume":"30","author":"Griffiths","year":"2016","journal-title":"J. Psychopharmacol. (Oxford)"},{"issue":"10","key":"10.1016\/j.schres.2026.03.003_bb0155","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1017\/S1461145713000722","article-title":"Serotonergic hallucinogens as translational models relevant to schizophrenia","volume":"16","author":"Halberstadt","year":"2013","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"4","key":"10.1016\/j.schres.2026.03.003_bb0160","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.biopsych.2015.02.020","article-title":"Depressive rumination, the default-mode network, and the dark matter of clinical neuroscience","volume":"78","author":"Hamilton","year":"2015","journal-title":"Biol. Psychiatry"},{"issue":"9","key":"10.1016\/j.schres.2026.03.003_bb0165","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1176\/appi.ajp.2016.15081035","article-title":"Efficacy and safety of antidepressants added to antipsychotics for schizophrenia: a systematic review and meta-analysis","volume":"173","author":"Helfer","year":"2016","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2026.03.003_bb0170","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.euroneuro.2025.09.011","article-title":"Efficacy, all-cause discontinuation, and safety of serotonergic psychedelics and MDMA to treat mental disorders: a living systematic review with meta-analysis","volume":"101","author":"H\u00f8jlund","year":"2025","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"2","key":"10.1016\/j.schres.2026.03.003_bb0175","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1177\/0269881114563634","article-title":"Glutamate and dopamine in schizophrenia: an update for the 21st century","volume":"29","author":"Howes","year":"2015","journal-title":"J. Psychopharmacol. (Oxford)"},{"issue":"1","key":"10.1016\/j.schres.2026.03.003_bb0180","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.biopsych.2016.07.014","article-title":"The role of genes, stress, and dopamine in the development of schizophrenia","volume":"81","author":"Howes","year":"2017","journal-title":"Biol. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2026.03.003_bb0185","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s12264-016-0090-1","article-title":"A review of the functional and anatomical default mode network in schizophrenia","volume":"33","author":"Hu","year":"2017","journal-title":"Neurosci. Bull."},{"issue":"4","key":"10.1016\/j.schres.2026.03.003_bb0190","doi-asserted-by":"crossref","DOI":"10.1192\/bjo.2023.535","article-title":"Psilocybin for treatment-resistant depression without psychedelic effects: study protocol for a 4-week, double-blind, proof-of-concept randomised controlled trial","volume":"9","author":"Husain","year":"2023","journal-title":"BJPsych open"},{"issue":"1","key":"10.1016\/j.schres.2026.03.003_bb0195","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1124\/pharmrev.120.000056","article-title":"Psychedelics in psychiatry: neuroplastic, immunomodulatory, and neurotransmitter mechanisms","volume":"73","author":"Inserra","year":"2021","journal-title":"Pharmacol. Rev."},{"issue":"6","key":"10.1016\/j.schres.2026.03.003_bb0200","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1001\/jamapsychiatry.2015.0071","article-title":"Large-scale network dysfunction in major depressive disorder: a meta-analysis of resting-state functional connectivity","volume":"72","author":"Kaiser","year":"2015","journal-title":"JAMA Psychiatry"},{"issue":"6","key":"10.1016\/j.schres.2026.03.003_bb1025","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1093\/schbul\/sbv060","article-title":"Disintegration of sensorimotor brain networks in schizophrenia","volume":"41","author":"Kaufmann","year":"2015","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2026.03.003_bb0205","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.schres.2016.05.003","article-title":"Secondary negative symptoms - a review of mechanisms, assessment and treatment","volume":"186","author":"Kirschner","year":"2017","journal-title":"Schizophr. Res."},{"issue":"25","key":"10.1016\/j.schres.2026.03.003_bb0210","doi-asserted-by":"crossref","first-page":"10544","DOI":"10.1523\/JNEUROSCI.3007-12.2013","article-title":"Activation of serotonin 2A receptors underlies the psilocybin-induced effects on \u03b1 oscillations, N170 visual-evoked potentials, and visual hallucinations","volume":"33","author":"Kometer","year":"2013","journal-title":"J. Neurosci."},{"issue":"5","key":"10.1016\/j.schres.2026.03.003_bb0215","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.euroneuro.2013.06.007","article-title":"The motivation and pleasure dimension of negative symptoms: neural substrates and behavioral outputs","volume":"24","author":"Kring","year":"2014","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"5","key":"10.1016\/j.schres.2026.03.003_bb0220","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1111\/acps.12873","article-title":"The relationship between negative symptoms and depression in schizophrenia: a systematic review","volume":"137","author":"Krynicki","year":"2018","journal-title":"Acta Psychiatr. Scand."},{"issue":"3","key":"10.1016\/j.schres.2026.03.003_bb1015","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1093\/schbul\/sbv186","article-title":"Mapping depression in schizophrenia: a functional magnetic resonance imaging study","volume":"42","author":"Kumari","year":"2016","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2026.03.003_bb0225","first-page":"357","article-title":"Experiences of psychedelic drug use among people with psychotic symptoms and disorders: personal growth and mystical experiences","volume":"8","author":"La Torre","year":"2024","journal-title":"J. Psychedelic Stud."},{"issue":"3","key":"10.1016\/j.schres.2026.03.003_bb0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.112203","article-title":"A non-hallucinogenic LSD analog with therapeutic potential for mood disorders","volume":"42","author":"Lewis","year":"2023","journal-title":"Cell Rep."},{"issue":"1","key":"10.1016\/j.schres.2026.03.003_bb0235","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41537-024-00485-x","article-title":"Advances in the study of phencyclidine-induced schizophrenia-like animal models and the underlying neural mechanisms","volume":"10","author":"Li","year":"2024","journal-title":"Schizophrenia"},{"issue":"10","key":"10.1016\/j.schres.2026.03.003_bb0240","doi-asserted-by":"crossref","first-page":"4859","DOI":"10.1038\/s41380-025-03080-3","article-title":"Long term safety of ADHD medication in patients with schizophrenia spectrum disorders","volume":"30","author":"Luykx","year":"2025","journal-title":"Mol. Psychiatry"},{"issue":"11","key":"10.1016\/j.schres.2026.03.003_bb0245","doi-asserted-by":"crossref","first-page":"3170","DOI":"10.1016\/j.celrep.2018.05.022","article-title":"Psychedelics promote structural and functional neural plasticity","volume":"23","author":"Ly","year":"2018","journal-title":"Cell Rep."},{"issue":"6","key":"10.1016\/j.schres.2026.03.003_bb0250","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1007\/s43440-023-00546-5","article-title":"Psychedelics action and schizophrenia","volume":"75","author":"Ma\u0107kowiak","year":"2023","journal-title":"Pharmacol. Rep."},{"issue":"3","key":"10.1016\/j.schres.2026.03.003_bb0255","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1177\/0269881114568040","article-title":"Peak experiences and the afterglow phenomenon: when and how do therapeutic effects of hallucinogens depend on psychedelic experiences?","volume":"29","author":"Maji\u0107","year":"2015","journal-title":"J. Psychopharmacol. (Oxford)"},{"issue":"12","key":"10.1016\/j.schres.2026.03.003_bb0260","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1038\/s41386-024-01912-4","article-title":"Effects of psychedelic, DOI, on nucleus accumbens dopamine signaling to predictable rewards and cues in rats","volume":"49","author":"Martin","year":"2024","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"10.1016\/j.schres.2026.03.003_bb0265","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/wps.21120","article-title":"Treatment-resistant depression: definition, prevalence, detection, management, and investigational interventions","volume":"22","author":"McIntyre","year":"2023","journal-title":"World Psychiatry"},{"key":"10.1016\/j.schres.2026.03.003_bb0270","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1093\/schbul\/sbs075","article-title":"Capturing the angel in \u201cangel dust\u201d: twenty years of translational neuroscience studies of NMDA receptor antagonists in animals and humans","volume":"38","author":"Moghaddam","year":"2012","journal-title":"Schizophr. Bull."},{"issue":"1","key":"10.1016\/j.schres.2026.03.003_bb0275","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1177\/02698811221131997","article-title":"Risks and benefits of psilocybin use in people with bipolar disorder: an international web-based survey on experiences of \u201cmagic mushroom\u201d consumption","volume":"37","author":"Morton","year":"2023","journal-title":"J. Psychopharmacol. (Oxford)"},{"issue":"11","key":"10.1016\/j.schres.2026.03.003_bb0280","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.tics.2025.07.006","article-title":"The emotional architecture of the psychedelic brain","volume":"29","author":"Moujaes","year":"2025","journal-title":"Trends Cogn. Sci."},{"key":"10.1016\/j.schres.2026.03.003_bb0285","article-title":"Therapeutic alliance and rapport modulate responses to psilocybin assisted therapy for depression","volume":"12","author":"Murphy","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"7","key":"10.1016\/j.schres.2026.03.003_bb0290","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1038\/nrd.2017.16","article-title":"Targeting glutamate signalling in depression: progress and prospects","volume":"16","author":"Murrough","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"issue":"2","key":"10.1016\/j.schres.2026.03.003_bb0295","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1001\/jamapsychiatry.2024.3532","article-title":"Emergency department visits involving hallucinogen use and risk of schizophrenia spectrum disorder","volume":"82","author":"Myran","year":"2025","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.schres.2026.03.003_bb0300","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2019.107426","article-title":"The origin of NMDA receptor hypofunction in schizophrenia","volume":"205","author":"Nakazawa","year":"2020","journal-title":"Pharmacol. Ther."},{"issue":"7966","key":"10.1016\/j.schres.2026.03.003_bb0305","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1038\/s41586-023-06204-3","article-title":"Psychedelics reopen the social reward learning critical period","volume":"618","author":"Nardou","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.schres.2026.03.003_bb0310","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.2147\/DDDT.S443177","article-title":"The promise of therapeutic psilocybin: an evaluation of the 134 clinical trials, 54 potential indications, and 0 marketing approvals on ClinicalTrials.gov","volume":"18","author":"Norring","year":"2024","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.schres.2026.03.003_bb0315","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.euroneuro.2023.07.011","article-title":"Psilocybin-assisted therapy for depression: a systematic review and dose-response meta-analysis of human studies","volume":"76","author":"Perez","year":"2023","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"3","key":"10.1016\/j.schres.2026.03.003_bb0320","doi-asserted-by":"crossref","DOI":"10.1111\/jnc.70020","article-title":"Serotonergic psychedelics rapidly modulate evoked glutamate release in cultured cortical neurons","volume":"169","author":"Petru\u0161kov\u00e1","year":"2025","journal-title":"J. Neurochem."},{"key":"10.1016\/j.schres.2026.03.003_bb0325","doi-asserted-by":"crossref","DOI":"10.1016\/j.neubiorev.2022.104706","article-title":"The emerging science of microdosing: a systematic review of research on low dose psychedelics (1955-2021) and recommendations for the field","volume":"139","author":"Polito","year":"2022","journal-title":"Neurosci. Biobehav. Rev."},{"issue":"7","key":"10.1016\/j.schres.2026.03.003_bb0330","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1073\/pnas.1815129116","article-title":"Effective connectivity changes in LSD-induced altered states of consciousness in humans","volume":"116","author":"Preller","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"10.1016\/j.schres.2026.03.003_bb0335","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1093\/schbul\/sbx043","article-title":"Effectiveness of prescription-based CNS stimulants on hospitalization in patients with schizophrenia: a nation-wide register study","volume":"44","author":"Rohde","year":"2018","journal-title":"Schizophr. Bull."},{"issue":"12","key":"10.1016\/j.schres.2026.03.003_bb0340","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1177\/0269881116675512","article-title":"Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial","volume":"30","author":"Ross","year":"2016","journal-title":"J. Psychopharmacol. (Oxford)"},{"issue":"4","key":"10.1016\/j.schres.2026.03.003_bb0345","doi-asserted-by":"crossref","first-page":"E234","DOI":"10.1503\/jpn.250005","article-title":"Treatment of depressive and negative symptoms in individuals with schizoaffective disorders using serotoninergic psychedelics: a case report","volume":"50","author":"Sab\u00e9","year":"2025","journal-title":"J. Psychiatry Neurosci."},{"key":"10.1016\/j.schres.2026.03.003_bb0350","doi-asserted-by":"crossref","DOI":"10.1038\/s41380-024-02800-5","article-title":"Reconsidering evidence for psychedelic-induced psychosis: an overview of reviews, a systematic review, and meta-analysis of human studies","author":"Sab\u00e9","year":"2025","journal-title":"Mol. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2026.03.003_bb0355","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/s41380-022-01721-5","article-title":"Schizophrenia and psychedelic state: dysconnection versus hyper-connection. A perspective on two different models of psychosis stemming from dysfunctional integration processes","volume":"28","author":"Sapienza","year":"2023","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.schres.2026.03.003_bb0360","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26188949","article-title":"Microdosing psychedelics to restore synaptic density in schizophrenia","author":"Sapienza","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.schres.2026.03.003_bb1035","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.biopsych.2018.11.011","article-title":"Common dysfunction of large-scale neurocognitive networks across psychiatric disorders","volume":"85","author":"Sha","year":"2019","journal-title":"Biol. Psychiatry"},{"issue":"16","key":"10.1016\/j.schres.2026.03.003_bb0365","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1016\/j.neuron.2021.06.008","article-title":"Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo","volume":"109","author":"Shao","year":"2021","journal-title":"Neuron"},{"key":"10.1016\/j.schres.2026.03.003_bb0370","doi-asserted-by":"crossref","DOI":"10.1001\/jamapsychiatry.2024.0047","article-title":"Adolescent psychedelic use and psychotic or manic symptoms","author":"Simonsson","year":"2024","journal-title":"JAMA Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2026.03.003_bb0375","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1192\/bjp.bp.109.067710","article-title":"Efficacy of antidepressants in treating the negative symptoms of chronic schizophrenia: meta-analysis","volume":"197","author":"Singh","year":"2010","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.schres.2026.03.003_bb0380","doi-asserted-by":"crossref","first-page":"757","DOI":"10.2147\/TCRM.S117321","article-title":"Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review","volume":"13","author":"Solmi","year":"2017","journal-title":"Ther. Clin. Risk Manag."},{"issue":"1","key":"10.1016\/j.schres.2026.03.003_bb0385","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/s41380-021-01161-7","article-title":"Age at onset of mental disorders worldwide: large-scale meta-analysis of 192 epidemiological studies","volume":"27","author":"Solmi","year":"2022","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.schres.2026.03.003_bb0390","doi-asserted-by":"crossref","DOI":"10.1038\/s41386-024-01972-6","article-title":"Acute effects of MDMA, MDA, lysine-MDMA, and lysine-MDA in a randomized, double-blind, placebo-controlled, crossover trial in healthy participants","author":"Straumann","year":"2025","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.schres.2026.03.003_bb0395","doi-asserted-by":"crossref","DOI":"10.3390\/jcm13185637","article-title":"Pharmacological treatments of negative symptoms in schizophrenia\u2014an update","author":"Tsapakis","year":"2024","journal-title":"J. Clin. Med."},{"issue":"7","key":"10.1016\/j.schres.2026.03.003_bb0400","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1080\/03007995.2021.1895095","article-title":"Review and meta-analysis of add-on tranylcypromine with antipsychotic drugs for the treatment of schizophrenia with predominant negative symptoms: a restoration of evidence","volume":"37","author":"Ulrich","year":"2021","journal-title":"Curr. Med. Res. Opin."},{"issue":"2","key":"10.1016\/j.schres.2026.03.003_bb0405","first-page":"240","article-title":"Depression and schizophrenia: cause, consequence, or trans-diagnostic issue?","volume":"43","author":"Upthegrove","year":"2017","journal-title":"Schizophr. Bull."},{"issue":"5","key":"10.1016\/j.schres.2026.03.003_bb0410","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/S0361-9230(01)00646-3","article-title":"A systems model of altered consciousness: integrating natural and drug-induced psychoses","volume":"56","author":"Vollenweider","year":"2001","journal-title":"Brain Res. Bull."},{"issue":"9","key":"10.1016\/j.schres.2026.03.003_bb0415","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/nrn2884","article-title":"The neurobiology of psychedelic drugs: implications for the treatment of mood disorders","volume":"11","author":"Vollenweider","year":"2010","journal-title":"Nat. Rev. Neurosci."},{"issue":"1","key":"10.1016\/j.schres.2026.03.003_bb0420","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0924-977X(96)00039-9","article-title":"Metabolic hyperfrontality and psychopathology in the ketamine model of psychosis using positron emission tomography (PET) and [18F]fluorodeoxyglucose (FDG)","volume":"7","author":"Vollenweider","year":"1997","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"17","key":"10.1016\/j.schres.2026.03.003_bb0425","doi-asserted-by":"crossref","DOI":"10.1097\/00001756-199812010-00024","article-title":"Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action","volume":"9","author":"Vollenweider","year":"1998","journal-title":"Neuroreport"},{"key":"10.1016\/j.schres.2026.03.003_bb0430","article-title":"Evidence of a dissociation pattern in default mode subnetwork functional connectivity in schizophrenia","volume":"5","author":"Wang","year":"2015","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.schres.2026.03.003_bb0435","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/BF00412109","article-title":"Comparison of psilocin with psilocybin, mescaline and LSD-25","volume":"3","author":"Wolbach","year":"1962","journal-title":"Psychopharmacologia"},{"issue":"18","key":"10.1016\/j.schres.2026.03.003_bb0440","doi-asserted-by":"crossref","first-page":"9078","DOI":"10.1073\/pnas.1900390116","article-title":"Reduced default mode network functional connectivity in patients with recurrent major depressive disorder","volume":"116","author":"Yan","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"20","key":"10.1016\/j.schres.2026.03.003_bb1010","doi-asserted-by":"crossref","first-page":"7438","DOI":"10.1073\/pnas.1405289111","article-title":"Altered global brain signal in schizophrenia","volume":"111","author":"Yang","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.schres.2026.03.003_bb0445","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.jpsychires.2024.01.014","article-title":"The combination of oxytocin and mindfulness-based group therapy for empathy and negative symptoms in schizophrenia spectrum disorders - a double-blinded, randomized, placebo-controlled pilot study","volume":"171","author":"Zierhut","year":"2024","journal-title":"J. Psychiatr. Res."}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996426000800?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996426000800?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T02:55:46Z","timestamp":1775789746000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996426000800"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":95,"alternative-id":["S0920996426000800"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2026.03.003","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Psychedelics for treatment of negative symptoms and depressive symptoms in schizophrenia spectrum disorder: A narrative review","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2026.03.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}